U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19. "The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies. The antiviral is being currently tested in a Phase 2/3 trial that is set to be completed in May. Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to generate desired immune responses, prompting it to abandon the program in January. REUTERS
ios developer account
buyappleacc.com selling ios developer account for lowest price and best quality, choose us, you will never regret. take one little step with us, you can enjoy the best services.